Coherus Oncology, Inc.
CHRS Healthcare Biotechnology
In the quarter to June 2026, revenue grew 39.5%, EPS fell 105.1%, free cash flow fell 33.2% and total debt rose 1.03%, each against the same quarter a year earlier.
Follow CHRS
Coherus Oncology, Inc. (CHRS) Beneish M-score
Coherus Oncology, Inc.'s Beneish M-score for fiscal 2025 is −3.44; values above −1.78 are the model's flag for possible earnings manipulation — a statistical screen, not a finding.
Beneish M-score, annual
Embed this chart
Annual newest first
| Period | Beneish M-score | Change (points) |
|---|---|---|
| FY2025 | −3.44 | (0.23) |
| FY2024 | −3.21 | (1.82) |
| FY2023 | −1.39 | 1.38 |
| FY2022 | −2.77 | 1.64 |
| FY2021 | −4.41 | (1.92) |
| FY2020 | −2.50 | (7.40) |
| FY2016 | 4.91 | 10.71 |
| FY2015 | −5.80 | — |
How fiscal 2025’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Days’ sales in receivables index | 0.09 | — | 0.09 | |
| Gross margin index | 1.00 | — | 0.53 | |
| Asset quality index | 0.84 | — | 0.34 | |
| Sales growth index | 1.60 | — | 1.43 | |
| Depreciation index | 0.90 | — | 0.10 | |
| SG&A index | 0.50 | — | −0.09 | |
| Total accruals to total assets | (0.17) | — | −0.81 | |
| Leverage index | 0.56 | — | −0.18 | |
| Beneish M-score | Low — no pattern the model associates with manipulation | −3.44 | ||
How the Beneish M-score works
M = −4.84 + 0.920 × DSRI + 0.528 × GMI + 0.404 × AQI + 0.892 × SGI + 0.115 × DEPI − 0.172 × SGAI + 4.679 × TATA − 0.327 × LVGI (Beneish, 1999): eight changes in the accounts from one fiscal year to the next, which the model weighs for the pattern seen in companies that later restated their earnings. Higher is worse.
| below −2.22 | Low — no pattern the model associates with manipulation |
|---|---|
| −2.22 to −1.78 | Elevated |
| above −1.78 | Flagged by the model |
−1.78 is the cut-off usually quoted from the paper, −2.22 a common conservative one. A statistical screen, not a finding of wrongdoing.
When asset quality, depreciation or SG&A cannot be worked out, that index is set to 1, as Beneish did, and the breakdown says so; with all three missing there is no score. Depreciation includes amortisation, and asset quality leaves out securities. Not worked out for banks, insurers and REITs.
Beneish M-score against peers
| Company | Beneish M-score |
|---|---|
| MDWD MediWound Ltd. compare | −3.7× |
| CHRS Coherus Oncology, Inc. | −3.4× |
| IPHA Innate Pharma S.A. Sponsored ADR compare | 1.1× |
| ADAG Adagene Inc. Sponsored ADR compare | 62.0× |
| CMPX Compass Therapeutics, Inc. compare | — |
| ORMP Oramed Pharmaceuticals Inc. compare | — |
| WHWK Whitehawk Therapeutics, Inc. compare | — |
| DTIL Precision BioSciences, Inc. compare | — |
| VRXA Veraxa Biotech AG compare | — |
What Beneish M-score is
The Beneish M-Score combines eight year-on-year changes in the accounts into a statistical screen for patterns seen in companies that overstated earnings.
−4.84 + 0.920 × DSRI + 0.528 × GMI + 0.404 × AQI + 0.892 × SGI + 0.115 × DEPI − 0.172 × SGAI + 4.679 × TATA − 0.327 × LVGI